Compare ADMA Biologics Inc (ADMA) vs Freeport-McMoRan Inc (FCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Freeport-McMoRan Inc — how do they compare? ADMA Biologics Inc trades at $9.35 (market cap $2.19B), while Freeport-McMoRan Inc trades at $66.86 (market cap $96.91B). The key difference: Freeport-McMoRan Inc is far larger — about 44.3× ADMA Biologics Inc's market cap, and Freeport-McMoRan Inc pays a 0.87% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | FCX | |
|---|---|---|
Market Cap | $2.19B | $96.91B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $71.73 |
52-Week Low | $7.60 | $35.34 |
Enterprise Value | $2.26B | $103.19B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.
The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →
